http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104293794-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-115 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate | 2014-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104293794-B |
| titleOfInvention | Nucleic acid aptamers specifically combined with beta-amyloid precursor protein lyase 1 and application of aptamers |
| abstract | The invention discloses nucleic acid aptamers specifically combined with beta-amyloid precursor protein lyase 1 and an application of the nucleic acid aptamers. The nucleotide sequences of the nucleic acid aptamers are any one of SEQ ID NO: 1 and SEQ ID NO: 2. The nucleic acid aptamers or chemical modifiers of the nucleic acid aptamers serving as BACE1 inhibitors can be applied to preparing drugs for treating Alzheimer's disease. The DNA aptamers A1 and A4 which can be combined with BACE1 with high affinity are successfully screened by virtue of an SELEX technology in the research, and the aptamers have the effect of inhibiting the in vitro activity of the BACE1. The nucleic acid aptamers are used for providing a research basis on development of novel potent and specific BACE1 inhibitors and providing novel methods and concepts to treatment of AD. |
| priorityDate | 2014-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 168.